MDACC Study No:2010-0692 ( NCT No: NCT01191801)
Title:A Phase 3, Randomized, Controlled, Double-Blind , Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Cytarabine; Vosaroxin
Study Status:Closed
Study Description:The goal of this clinical research study is to compare the safety and
effectiveness of combining cytarabine with the study drug vosaroxin, versus
cytarabine and a placebo, in treating patients with relapsed or refractory
AML. Researchers want to compare how long these 2 study drug combinations may
be able to help control the disease.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase III
Treatment Agents:Cytarabine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Sunesis Pharmaceuticals, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults